Nugene Biopharma acquires SkinGuardian


Nugene International expands high tech skin care products

Nugene Biopharma, a subsidiary of Nugene International, a company that focuses on age-defying aesthetic products for skin and hair, has acquired SkinGuardian - an FDA-approved skin protectant, antiseptic and moisturizing topical cream.

“This is a prime example of the type of synergistic acquisitions we intend to make that will expand our range of opportunities while significantly reducing our time to market,” said Ali Kharazmi, Nugene International’s CEO.

Nugene acquired all intellectual property held by SkinGuardian and its founder and owner, Chris O’Brien, who will provide ongoing consulting to Nugene International. The acquisition includes the company trademark, all formulae and derivatives under the patent, clinical trial data, as well as the underlying patent via which the technology is protected.

Nugene BioPharma was formed as a division of Nugene International to acquire and develop FDA-approved products that treat various conditions based upon stem cell technology and the acquisition of SkinGuardian will be a step to achieving these goals. “NuGene's technologies and applications extend beyond the cosmeceutical and hair care market, the focus of NuGene International," explained Kharazmi. "We decided to form NuGene BioPharma in order to develop and market FDA-approved products that have pharmacological properties that can enhance the healing of wounds and skin conditions."

Sign up for your free email newsletter

"We see this FDA-approved topical cream as the foundation for a variety of topical treatments.” Kharazmi continued. SkinGuardian provides an antimicrobial composition that can be used against a variety of microorganisms including bacteria, fungi and viruses. It serves as an effective guard against infections and also for damaged and undamaged skin. The antimicrobial composition has also proved to be effective against viruses.